WHAT IS CLAIMED IS:

1. A method of treating thrombocytopenia in a human in need thereof which comprises administering a load dose of the compound 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid or a pharmaceutically acceptable salt thereof,

wherein the load dose of the compound, or pharmaceutically acceptable salt thereof, is an amount ranging from about 50 mg to about 150 mg administered from 2 to 4 times in a day for from 1 to 14 days, or is an amount ranging from about 200 mg to about 600 mg administered once a day for from 1 to 14 days,

followed by the administration of a maintenance dose of the compound, or pharmaceutically acceptable salt thereof,

wherein the maintenance dose of the compound, or pharmaceutically acceptable salt thereof, is an amount of from about 25 mg to about 150 mg a day for at least two additional days.

2. The method of Claim 1, wherein the compound is 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine).

3. The method of Claim 2, wherein the load dose for the compound is an amount ranging from about 200 mg to about 600 mg administered once a day for from 1 to 7 days.

4. The method of Claim 3, wherein the maintenance dose of the compound is an amount of about 50 mg.

5. The method of Claim 3, wherein the maintenance dose of the compound is an amount of about 75 mg.

6. The method of Claim 3, wherein the maintenance dose of the compound is an amount of about 150 mg.

7. A method of treating neutropenia in a human in need thereof which comprises administering a load dose of the compound 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid or a pharmaceutically acceptable salt thereof,

wherein the load dose of the compound, or pharmaceutically acceptable salt thereof, is an amount ranging from about 50 mg to about 150 mg administered from 2 to 4 times in a day for from 1 to 14 days, or is an amount ranging from about 200 mg to about 600 mg administered once a day for from 1 to 14 days,

followed by the administration of a maintenance dose of the compound, or pharmaceutically acceptable salt thereof,

wherein the maintenance dose of the compound, or pharmaceutically acceptable salt thereof, is an amount of from about 25 mg to about 150 mg a day for at least two additional days.

8. The method of Claim 7, wherein the compound is 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine).

9. The method of Claim 8, wherein the load dose for the compound is or is an amount ranging from about 200 mg to about 600 mg administered once a day for from 1 to 7 days.

10. The method of Claim 9, wherein the maintenance dose of the compound is an amount of about 50 mg.

11. The method of Claim 9, wherein the maintenance dose of the compound is an amount of about 75 mg.

12. The method of Claim 9, wherein the maintenance dose of the compound is an amount of about 150 mg.

13. A method of increasing platelet production in a human in need thereof which comprises administering a load dose of the compound 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid or a pharmaceutically acceptable salt thereof,

wherein the load dose of the compound, or pharmaceutically acceptable salt thereof, is an amount ranging from about 50 mg to about 150 mg administered from 2 to 4 times in a day for from 1 to 14 days, or is an amount ranging from about 200 mg to about 600 mg administered once a day for from 1 to 14 days,

followed by the administration of a maintenance dose of the compound, or pharmaceutically acceptable salt thereof,

wherein the maintenance dose of the compound, or pharmaceutically acceptable salt thereof, is an amount of from about 25 mg to about 150 mg a day for at least two additional days.

14. The method of Claim 13, wherein the compound is 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine).

15. The method of Claim 14, wherein the load dose for the compound is or is an amount ranging from about 200 mg to about 600 mg administered once a day for from 1 to 7 days.

16. The method of Claim 15, wherein the maintenance dose of the compound is an amount of about 50 mg.

17. The method of Claim 15, wherein the maintenance dose of the compound is an amount of about 75 mg.

18. The method of Claim 15, wherein the maintenance dose of the compound is an amount of about 150 mg.

19. The method of Claim14, wherein the platelet production is increased prior to platelet pheresis, blood donation or platelet donation.

20. A method for enhancing the number of peripheral blood stem cells obtained from a donor comprising administering a load dose of the compound 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid or a pharmaceutically acceptable salt thereof, prior to leukapheresis,

wherein the load dose of the compound, or pharmaceutically acceptable salt thereof, is an amount ranging from about 50 mg to about 150 mg administered from 2 to 4 times in a day for from 1 to 14 days, or is an amount ranging from about 200 mg to about 600 mg administered once a day for from 1 to 14 days,

followed by the administration of a maintenance dose of the compound, or pharmaceutically acceptable salt thereof,

wherein the maintenance dose of the compound, or pharmaceutically acceptable salt thereof, is an amount of from about 25 mg to about 150 mg a day for at least two additional days.

21. The method of Claim 20 further comprising co-administering a hematopoietic-cell mobilizing agent selected from the group consisting of: a colony stimulating factor, cytokine, chemokine, interleukin or cytokine receptor agonist, adhesion molecule antagonists or antibodies.

22. The method of Claim 21, wherein the mobilizing agent is selected from the group consisting of G-CSF, GM-CSF, TPO, EPO, Gro-beta, IL-8, cytoxan, VLA-4 inhibitors, SCF, FLT3 ligand or a biologically active derivative of G-CSF, GM-CSF, TPO, EPO, Gro-beta and IL-8.

23. A method of treating thrombocytopenia in a human in need thereof which comprises administering a load dose of the compound 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid or a pharmaceutically acceptable salt thereof,

followed by the administration of a maintenance dose of the compound, or pharmaceutically acceptable salt thereof,

wherein the maintenance dose of the compound, or pharmaceutically acceptable salt thereof, is an amount lower than the load dose and is administered for at least two days.

24. The method of Claim 23, wherein the compound is 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine).

25. The method of Claim 24, wherein the load dose for the compound is or is an amount ranging from about 200 mg to about 600 mg administered once a day for from 1 to 7 days.

26. The method of Claim 25, wherein the maintenance dose of the compound is an amount of about 75 mg.

27. The method of Claim 25, wherein the maintenance dose of the compound is an amount of about 100 mg.

28. The method of Claim 25, wherein the maintenance dose of the compound is an amount of about 150 mg.

29. A method of treating neutropenia in a human in need thereof which comprises administering a load dose of the compound 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid or a pharmaceutically acceptable salt thereof,

followed by the administration of a maintenance dose of the compound, or pharmaceutically acceptable salt thereof,

wherein the maintenance dose of the compound, or pharmaceutically acceptable salt thereof, is an amount lower than the load dose and is administered for at least two days.

30. A method of treating thrombocytopenia in a human in need thereof which comprises administering a high dose of the compound 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid or a pharmaceutically acceptable salt thereof,

wherein the high dose of the compound, or pharmaceutically acceptable salt thereof, is an amount ranging from about 125mg to about 400mg administered per day for at least 21 days

.

31. The method of Claim 30, wherein the compound is 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine).

32. The method of Claim 31, wherein the high dose of the compound is an amount ranging from about 150mg to about 300mg administered once a day for from 1 to 21 days.

33. The method of Claim 31, wherein the high dose of the compound is an amount ranging from about 150mg to about 300mg administered once a day for at least 5 days.

34. The method of Claim 31, wherein the high dose of the compound is an amount ranging from about 150mg to about 300mg administered once a day for at least 10 days.

35. The method of Claim 31, wherein the high dose of the compound is an amount ranging from about 150mg to about 300mg administered once a day for at least 14 days.

36. The method of Claim 31, wherein the high dose of the compound is an amount ranging from about 150mg to about 300mg administered once a day for at least 21 days.

37. A pharmaceutical composition comprising from about 125mg to about 400mg of the compound 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) and a pharmaceutical carrier.

38. A pharmaceutical composition comprising from about 125mg to about 300mg of the compound 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) and a pharmaceutical carrier.

WHAT IS CLAIMED IS:

1. Use of a load dose of the compound 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of thrombocytopenia in a human in need thereof, wherein when administered the load dose of the compound, or pharmaceutically acceptable salt thereof, is an amount ranging from about 50 mg to about 150 mg administered from 2 to 4 times in a day for 1 to 14 days, or is an amount ranging from about 200 mg to about 600 mg administered once a day for 1 to 14 days, and administration is followed by a maintenance dose of the compound, or pharmaceutically acceptable salt thereof, wherein the maintenance dose of the compound, or pharmaceutically acceptable salt thereof, is an amount of from about 25 mg to about 150 mg a day for at least two additional days.

2. Use of a load dose of the compound 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for increasing platelet production in a human in need thereof, wherein when administered the load dose of the compound, or pharmaceutically acceptable salt thereof, is an amount ranging from about 50 mg to about 150 mg administered from 2 to 4 times in a day for 1 to 14 days, or is an amount ranging from about 200 mg to about 600 mg administered once a day for 1 to 14 days, and administration is followed by a maintenance dose of the compound, or pharmaceutically acceptable salt thereof, wherein the maintenance dose of the compound, or pharmaceutically acceptable salt thereof, is an amount of from about 25 mg to about 150 mg a day for at least two additional days.